- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06921421
Assessment Of Burn Severity and Extent Spatial Frequency Domain Imaging
April 8, 2025 updated by: Rodney Chan, The Metis Foundation
Assessment Of Burn Severity and Extent Spatial Frequency Domain Imaging (SFDI): An Observational Pilot Study
The goal of this pilot clinical study is to evaluate the feasibility of collecting Spatial Frequency Domain Imaging (SFDI) data in patients with circulatory compromise due to thermal burns using the FDA-cleared Clarifi Imaging System and the next generation handheld m-Clarifi.
Accurate assessment of burn depth and assessment at the point of care is an essential input for clinicians to plan proper treatment and management.
SFDI has been shown to be a promising method to evaluate burn depth and extent within 24 hours in pre-clinical studies.
The two feasibility goals of this study are as follows: 1) Do the values obtained with a commercial SFDI system provide utility in assessing burn depth in a clinical setting?
And 2) Do Clarifi and m-Clarifi provide equivalent data when assessing subjects with burn injuries (biomarker imaging values, clinical workflow).
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
15
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Victoria Diaz, BSN
- Phone Number: 210-201-2206
- Email: diaz@metisfoundationusa.org
Study Locations
-
-
Texas
-
Fort Sam Houston, Texas, United States, 78234
- The United States Army Institute of Surgical Resarch
-
Contact:
- Kristin Anselmo
- Phone Number: 2105691138
- Email: kanselmo@metisfoundationusa.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Patients receiving care at the US Army Institute of Surgical Research (USAISR) Burn Center with thermal burn injuries will be considered for enrollment into this study
Description
Inclusion Criteria:
- Patients 18 years of age or older
- Thermal burns of any depth (superficial, deep partial thickness, or full thickness).
Exclusion Criteria:
- Patients less than 18 years of age
- Pregnant or breastfeeding women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean SFDI Scattering Parameter (mm-¹) at Burn Injury Sites Using Clarifi and m-Clarifi Imaging Systems
Time Frame: From enrollment to 21 days
|
This outcome will report the mean value of the scattering coefficient (μs'), a quantitative SFDI-derived biomarker that correlates with burn depth, measured at specified time points (Day 0, 3, 7, 14, and 21) using the Clarifi and m-Clarifi imaging systems.
Higher scattering values are associated with deeper tissue damage.
|
From enrollment to 21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation Between SFDI Scattering Parameter and Clinician-Determined Burn Depth
Time Frame: From enrollment to 21 days
|
This outcome evaluates the statistical correlation between SFDI scattering values and the burn depth classifications made by clinicians based on visual assessment and standard clinical criteria (e.g., superficial partial, deep partial, full thickness).
|
From enrollment to 21 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Agreement Between Clarifi and m-Clarifi Devices in Measuring SFDI Scattering Parameter
Time Frame: From enrollment to 21 days
|
This outcome assesses the agreement between SFDI scattering measurements obtained from the Clarifi (FDA-cleared) and m-Clarifi (handheld prototype) devices at the same anatomical burn sites.
Agreement will be quantified using Bland-Altman analysis and intraclass correlation coefficients (ICCs).
|
From enrollment to 21 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Rodney Chan, MD, The Metis Foundation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 1, 2025
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
March 7, 2025
First Submitted That Met QC Criteria
April 8, 2025
First Posted (Actual)
April 10, 2025
Study Record Updates
Last Update Posted (Actual)
April 10, 2025
Last Update Submitted That Met QC Criteria
April 8, 2025
Last Verified
April 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-25-017
- MTEC-22-08-BDA-007 (Other Grant/Funding Number: Medical Technology Enterprise Consortium)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burn
-
Dr Muhammad Naveed ShahzadNot yet recruitingSilver Sulfadiazine With Hyaluronic Acid Versus Silver Sulfadiazine Alone in Partial-Thickness BurnsPartial-Thickness Burn, Thermal BurnPakistan
-
Indonesia UniversityRecruitingBurn Degree Second | Burn Degree ThirdIndonesia
-
Xequel Bio, Inc.United States Department of DefenseWithdrawnThermal Burn | Second Degree Burn
-
Integra LifeSciences CorporationWithdrawnBurn Scar | Burn Injury | Skin Grafting | Burn Wounds - Partial Thickness (2nd Degree)
-
The First Affiliated Hospital of Xinxiang Medical...Not yet recruitingBurn | Burn Degree Second | Burn Contracture of Skin
-
XenoTherapeutics, Inc.Joseph M. Still Research Foundation, Inc.RecruitingWound Heal | Thermal Burn | Burn Degree Second | Burns Degree Third | Burn (Disorder)United States
-
General Electric ResearchTerminatedBurn Wound | 2nd Degree Burn of the SkinUnited States
-
University Hospital, LinkoepingCompletedBurn Scar | Burns | Burn Second DegreeSweden
-
University Hospital Schleswig-HolsteinUniversity of LuebeckRecruitingSecond-degree Burn | Third-Degree BurnGermany
-
Jason SperryUnited States Department of DefenseNot yet recruitingBurn Injury | Thermal BurnUnited States
Clinical Trials on Spatial Frequency Domain Imaging
-
University of California, IrvineEnrolling by invitationLung Diseases | Cancer, LungUnited States
-
University of California, IrvineBeckman Laser Institute University of California IrvineWithdrawnDisorders of Skin Grafts and FlapsUnited States
-
University of California, IrvineBeckman Laser Institute University of California IrvineWithdrawn
-
Boston UniversityScleroderma Clinical Trials Consortium (SCTC); Fibrosis ARC: Connecting Tissues...Active, not recruiting
-
Boston UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)RecruitingSystemic Scleroderma | Diffuse Cutaneous SclerodermaUnited States
-
University of Southern CaliforniaModulated Imaging Inc.CompletedSpatial Frequency Domain Imaging (SFD) for Assessment of Diabetic Foot Ulcer Development and HealingDiabetic Foot UlcerUnited States
-
Massachusetts General HospitalNational Cancer Institute (NCI)CompletedBarrett's EsophagusUnited States
-
Massachusetts General HospitalCompletedBiliary StrictureUnited States
-
Massachusetts General HospitalCompletedNon-Melanoma Skin Cancer (NMSC)United States
-
Lahey ClinicMassachusetts General Hospital; National Institutes of Health (NIH)WithdrawnLung Cancer | Pulmonary Disease | Squamous Cell Lung CancerUnited States